OOIR: Observatory of International Research

Papers

(The TQCC of Melanoma Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Impact of COVID-19 on melanoma diagnosis	18
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)	17
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials	17
Ultraviolet A radiation exposure and melanoma: a review	16
C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting	16
Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases	15
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma	12
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	11
Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature	11
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target	10
Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis	10
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma	10
Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis	10
Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study	10
The role of osteopontin in the development and metastasis of melanoma	10
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma	10
Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors	10
Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series	10
Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma	10
Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma	9
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors	9
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	9
Vitamin D deficiency in melanoma patients is associated with worse overall survival: a retrospective cohort study	8
Diagnostic and prognostic value of heat shock protein 90α in malignant melanoma	8
Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma	8

ETS1 promoted cell growth, metastasis and epithelial–mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression	7
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	7
Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review	7
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines	7
Influence of IL1B (rs16944) and IL1R2 (rs4141134) polymorphisms on aggressiveness and prognosis of cutaneous melanoma	7
Statin use is associated with improved overall survival in patients with melanoma	7
Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis	7
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1	7
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activ	7
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases	7
Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies	7
Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients	6
Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases	6
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma	6
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report	6
A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio	6
Risk factors in pediatric melanoma: a retrospective study of 39 cases	6
GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients	6
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy	6
Seborrheic keratosis-like melanoma: a diagnostic challenge	6
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	6
Antibody-drug conjugates: an evolving approach for melanoma treatment	6
A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas	6
Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells	6
The potential of using artificial intelligence to improve skin cancer diagnoses in Hawai‘i’s multiethnic population	6
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective	5
Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study	5
Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma	5
BAP1 deletion abrogates growth and metastasis of murine cutaneous melanoma	5
MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas	5
Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology	5
Expression of cathepsins B and D by cancer stem cells in head and neck metastatic malignant melanoma	5
Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma	5
The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective	5
Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis	5
Female melanoma and estrogen receptors expression: an immunohistochemical pilot study	5
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	5
PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma	5
Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression	5
Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitors	5
LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression	5
Uveal melanoma metastatic at initial diagnosis: a case series	4
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	4
Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and	4
Immunohistochemistry analysis reveals lysyl oxidase-like 3 as a novel prognostic marker for primary melanoma	4
Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10/STAT3 axis in melanoma tumor microenvironment	4
Treatment of in-transit melanoma metastases using intralesional PV-10	4
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma	4
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients	4
Real-world data on melanoma brain metastases and survival outcome	4

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors	4
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma	4
Induction of T helper 17 cell response by interleukin-7 in patients with primary cutaneous melanoma	4
PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review	4
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma	4
BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients	4